Current Report Filing (8-k)
November 05 2019 - 7:18AM
Edgar (US Regulatory)
0001578845
false
0001578845
2019-11-04
2019-11-05
0001578845
agn:OrdinaryShareParValue0.0001PerShareMember
2019-11-04
2019-11-05
0001578845
agn:FloatingRateNotesDue2020Member
2019-11-04
2019-11-05
0001578845
agn:Notes0.500PercentDue2021Member
2019-11-04
2019-11-05
0001578845
agn:Notes1.500PercentDue2023Member
2019-11-04
2019-11-05
0001578845
agn:Notes1.250PercentDue2024Member
2019-11-04
2019-11-05
0001578845
agn:Notes2.625PercentDue2028Member
2019-11-04
2019-11-05
0001578845
agn:Notes2.125PercentDue2029Member
2019-11-04
2019-11-05
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
WASHINGTON, D.C.
20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report
(Date of earliest event reported): November 5, 2019 (November 5, 2019)
ALLERGAN PLC
(Exact Name of
Registrant as Specified in Charter)
Ireland
|
|
001-36867
|
|
98-1114402
|
(State or Other
Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification
No.)
|
Clonshaugh Business and Technology Park
Coolock, Dublin,
D17 E400, Ireland
(Address of Principal
Executive Offices)
(862) 261-7000
(Registrant’s
telephone number, including area code)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Securities registered pursuant to Section 12(b)
of the Exchange Act:
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of
each exchange on which registered
|
Ordinary Share, par value $0.0001 per share
|
|
AGN
|
|
New York Stock Exchange
|
Floating rate notes due 2020
|
|
AGN20A
|
|
New York Stock Exchange
|
0.500% notes due 2021
|
|
AGN21
|
|
New York Stock Exchange
|
1.500% notes due 2023
|
|
AGN23A
|
|
New York Stock Exchange
|
1.250% notes due 2024
|
|
AGN24A
|
|
New York Stock Exchange
|
2.625% notes due 2028
|
|
AGN28
|
|
New York Stock Exchange
|
2.125% notes due 2029
|
|
AGN29
|
|
New York Stock Exchange
|
Item 2.02
|
Results of Operations and Financial Condition.
|
On November 5, 2019, Allergan plc (the
“Company”) issued a press release announcing its financial results for the three and nine months ended September 30,
2019. A copy of the press release reporting the financial results of the Company is attached to this report as Exhibit 99.1 and
incorporated herein by reference.
The information in this report (including
the exhibits) is furnished pursuant to Item 2.02 and shall not be deemed to be “filed” for purposes of Section 18
of the Securities Exchange Act of 1934 (the “Exchange Act”), nor shall it be deemed incorporated by reference in any
filing under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such
filing.
Item 9.01
|
Financial Statements and Exhibits.
|
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: November 5, 2019
|
Allergan plc
|
|
|
|
|
|
By:
|
/s/ Matthew M. Walsh
|
|
|
Name:
|
Matthew M. Walsh
|
|
|
Title:
|
EVP & Chief Financial Officer
|
EXHIBIT INDEX
Allergan (NYSE:AGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Allergan (NYSE:AGN)
Historical Stock Chart
From Sep 2023 to Sep 2024